TrialJournal of clinical pharmacology2014

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).

Shuji Ohta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.